Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

Drug development powered by artificial intelligence is countering incentives from the Inflation Reduction Act and making ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts disc ...

Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.

As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert ...

Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

The FDA granted orphan designation to Sanofi ( SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Published first on TheFly – ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to ...

Kymera has $900 million in cash and no long-term debt, funding operations into mid-2027. Click here to read an analysis of ...